{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:57:14Z","timestamp":1791619034045,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["22XD1421900"],"award-info":[{"award-number":["22XD1421900"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012600","name":"ShanghaiTech University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012600","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22177074"],"award-info":[{"award-number":["22177074"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22377077"],"award-info":[{"award-number":["22377077"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.bmcl.2024.129654","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:26:45Z","timestamp":1707870405000},"page":"129654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["2-Phenylcyclopropylmethylamine (PCPMA) as a privileged scaffold for central nervous system drug design"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6394-1258","authenticated-orcid":false,"given":"Huiqiong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6065-2682","authenticated-orcid":false,"given":"Jianjun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.129654_b0005","unstructured":"World Health Organization. Depressive disorder (depression). 2023 March. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression."},{"key":"10.1016\/j.bmcl.2024.129654_b0010","unstructured":"World Health Organization. Schizophrenia. 2022 January. https:\/\/www.who.int\/news-room\/factsheets\/detail\/schizo-phrenia."},{"key":"10.1016\/j.bmcl.2024.129654_b0015","unstructured":"World Health Organization. Parkinson disease. 2023 August. https:\/\/www.who.int\/news-room\/factsheets\/detail\/parkin-son disease."},{"key":"10.1016\/j.bmcl.2024.129654_b0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.bmcl.2024.129654_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115414","article-title":"Aporphines: a privileged scaffold in CNS drug discovery","volume":"256","author":"Zhu","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0030","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.apsb.2021.01.010","article-title":"Recent developments in the medicinal chemistry of single boron atom-containing compounds","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmcl.2024.129654_b0035","first-page":"536","article-title":"\u201cOld Friends in New Guise\u201d: exploiting privileged structures for scaffold re-evolution\/refining","volume":"17","author":"Song","year":"2014","journal-title":"Comb Chem High T Scr."},{"key":"10.1016\/j.bmcl.2024.129654_b0040","first-page":"1528","article-title":"Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry","volume":"19","author":"Song","year":"2013","journal-title":"Curr Pharm Design."},{"key":"10.1016\/j.bmcl.2024.129654_b0045","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1016\/j.bmc.2018.06.043","article-title":"Design, synthesis and docking study of 4-arylpiperazine carboxamides as monoamine neurotransmitters reuptake inhibitors","volume":"26","author":"Paudel","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0050","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1016\/j.bmcl.2007.07.083","article-title":"Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor","volume":"17","author":"Dalton King","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129654_b0055","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev-pharmtox-010814-124742","article-title":"MT1 and MT2 melatonin receptors: a therapeutic perspective","volume":"56","author":"Liu","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bmcl.2024.129654_b0060","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1021\/jm801354e","article-title":"Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action","volume":"52","author":"Cho","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0065","doi-asserted-by":"crossref","first-page":"17239","DOI":"10.1021\/acs.jmedchem.1c01327","article-title":"2-Phenylcyclopropylmethylamine derivatives as dopamine D2 receptor partial agonists: design, synthesis, and biological evaluation","volume":"64","author":"Yan","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0070","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bmcl.2010.12.135","article-title":"Identification of a new series of non-peptidic NK3 receptor antagonists","volume":"21","author":"Juhl","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129654_b0075","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1021\/jm200144j","article-title":"Novel potent and selective sigma ligands: evaluation of their agonist and antagonist properties","volume":"54","author":"Marrazzo","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0080","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0028-3908(85)90157-1","article-title":"Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug","volume":"24","author":"Moret","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2024.129654_b0085","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1021\/jm5019274","article-title":"Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents","volume":"58","author":"Cheng","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0090","doi-asserted-by":"crossref","first-page":"25532","DOI":"10.52965\/001c.25532","article-title":"Milnacipran for the treatment of fibromyalgia","volume":"9","author":"Gupta","year":"2021","journal-title":"Health Psychol Res"},{"key":"10.1016\/j.bmcl.2024.129654_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2017.11.056","article-title":"Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis","volume":"228","author":"Wagner","year":"2018","journal-title":"J Affect Disord"},{"key":"10.1016\/j.bmcl.2024.129654_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107423","article-title":"Inhibition of serotonin synthesis: A novel therapeutic paradigm","volume":"205","author":"Bader","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2024.129654_b0105","article-title":"Serotonin receptor and transporter endocytosis is an important factor in the cellular basis of depression and anxiety","volume":"15","author":"Deo","year":"2021","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.bmcl.2024.129654_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11916-016-0556-x","article-title":"Fibromyalgia pathogenesis and treatment options update","volume":"20","author":"Chinn","year":"2016","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.bmcl.2024.129654_b0115","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2024.129654_b0120","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1016\/j.bmcl.2008.04.025","article-title":"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors","volume":"18","author":"Tamiya","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129654_b0125","first-page":"CD011789","article-title":"Milnacipran for neuropathic pain in adults","volume":"2015","author":"Derry","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bmcl.2024.129654_b0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00003495-199856030-00010","article-title":"A review of its use in depression","volume":"56","author":"Spencer","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2024.129654_b0135","doi-asserted-by":"crossref","first-page":"e2212939","DOI":"10.1001\/jamanetworkopen.2022.12939","article-title":"Comparison of amitriptyline and US Food and drug administration-approved treatments for fibromyalgia: a systematic review and network meta-analysis","volume":"5","author":"Farag","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bmcl.2024.129654_b0140","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/1039856218794874","article-title":"Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant","volume":"26","author":"Keks","year":"2018","journal-title":"Australas Psychiatry"},{"key":"10.1016\/j.bmcl.2024.129654_b0145","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s40265-013-0116-1","article-title":"Levomilnacipran extended release: first global approval","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2024.129654_b0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/17512433.2014.889563","article-title":"Levomilnacipran: a newly approved drug for treatment of major depressive disorder","volume":"7","author":"Mago","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2024.129654_b0155","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.neuropharm.2013.02.024","article-title":"Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety","volume":"70","author":"Auclair","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2024.129654_b0160","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.bmcl.2008.01.011","article-title":"Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors","volume":"18","author":"Chen","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129654_b0165","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0014-2999(96)00803-5","article-title":"Melatonin together with noradrenaline augments contractions of human myometrium","volume":"316","author":"Martensson","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmcl.2024.129654_b0170","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1111\/bph.13950","article-title":"Melatonin receptors: molecular pharmacology and signalling in the context of system bias","volume":"175","author":"Cecon","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2024.129654_b0175","doi-asserted-by":"crossref","first-page":"pe39","DOI":"10.1126\/stke.2001.107.pe39","article-title":"Melatonin receptor signaling: finding the path through the dark","volume":"2001","author":"Masana","year":"2001","journal-title":"Sci STKE"},{"key":"10.1016\/j.bmcl.2024.129654_b0180","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/phar.1822","article-title":"Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep-wake disorders","volume":"36","author":"Williams","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bmcl.2024.129654_b0185","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-014-0200-1","article-title":"Tasimelteon: first global approval","volume":"74","author":"Dhillon","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2024.129654_b0190","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bmcl.2003.12.052","article-title":"Design and synthesis of benzoxazole derivatives as novel melatoninergic ligands","volume":"14","author":"Sun","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129654_b0195","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.bmcl.2005.01.015","article-title":"(R)-2-(4-Phenylbutyl)dihydrobenzofuran derivatives as melatoninergic agents","volume":"15","author":"Sun","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129654_b0200","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1021\/acs.jmedchem.6b01194","article-title":"Design and discovery of functionally selective serotonin 2C (5-HT(2C)) receptor agonists","volume":"59","author":"Cheng","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0205","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/acs.chemrev.3c00375","article-title":"Serotonin 2A receptor (5-HT2AR) agonists: psychedelics and non-hallucinogenic analogues as emerging antidepressants","volume":"124","author":"Duan","year":"2023","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2024.129654_b0210","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/cmdc.201500437","article-title":"We need 2C but not 2B: developing serotonin 2C (5-HT2C) receptor agonists for the treatment of CNS disorders","volume":"10","author":"Cheng","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2024.129654_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111626","article-title":"Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT2C) receptor agonist without 5-HT2B agonism","volume":"182","author":"Zhang","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0220","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cmdc.201000186","article-title":"HTS and rational drug design to generate a class of 5-HT2C-selective ligands for possible use in schizophrenia","volume":"5","author":"Kozikowski","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2024.129654_b0225","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1021\/ml200206z","article-title":"Rational drug design leading to the identification of a potent 5-HT2C agonist lacking 5-HT2B activity","volume":"2","author":"Chen","year":"2011","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129654_b0230","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/acs.jmedchem.5b01153","article-title":"Further advances in optimizing (2-phenylcyclopropyl)methylamines as novel serotonin 2C agonists: effects on hyperlocomotion, prepulse inhibition, and cognition models","volume":"59","author":"Cheng","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0235","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1021\/acs.jmedchem.7b00584","article-title":"Discovery of N-substituted (2-phenylcyclopropyl)methylamines as functionally selective serotonin 2C receptor agonists for potential use as antipsychotic medications","volume":"60","author":"Zhang","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0240","doi-asserted-by":"crossref","first-page":"9841","DOI":"10.1021\/acs.jmedchem.8b00435","article-title":"Biased ligands of G protein-coupled receptors (GPCRs): structure-functional selectivity relationships (SFSRs) and therapeutic potential","volume":"61","author":"Tan","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0245","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1021\/jm030064v","article-title":"Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT2A\/2C receptor ligands","volume":"46","author":"Chambers","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0250","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1016\/j.tetlet.2015.01.060","article-title":"Design and Synthesis of (2-(5-Chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)cyclopropyl)methanamine as a Selective Serotonin 2C Agonist","volume":"56","author":"Cheng","year":"2015","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmcl.2024.129654_b0255","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: from structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bmcl.2024.129654_b0260","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmcl.2024.129654_b0265","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1478-811X-11-34","article-title":"Complexity of dopamine metabolism","volume":"11","author":"Meiser","year":"2013","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.bmcl.2024.129654_b0270","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pneurobio.2016.03.011","article-title":"Polypharmacology of dopamine receptor ligands","volume":"142","author":"Butini","year":"2016","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bmcl.2024.129654_b0275","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1021\/acs.jmedchem.9b01835","article-title":"Design and synthesis of bitopic 2-phenylcyclopropylmethylamine (PCPMA) derivatives as selective dopamine D3 receptor ligands","volume":"63","author":"Tan","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0280","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41593-021-00971-w","article-title":"Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties","volume":"25","author":"Chen","year":"2022","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bmcl.2024.129654_b0285","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrd1905","article-title":"Opinion: NK3 receptor antagonists: the next generation of antipsychotics?","volume":"4","author":"Spooren","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2024.129654_b0290","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/14756366.2015.1021250","article-title":"Convergent QSAR studies on a series of NK3 receptor antagonists for schizophrenia treatment","volume":"31","author":"Primi","year":"2016","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0295","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1111\/bph.13076","article-title":"The effects of sigma (sigma1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice","volume":"172","author":"Malik","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2024.129654_b0300","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2024.129654_b0305","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4155\/fmc-2017-0164","article-title":"Novel Sigma-1 receptor antagonists: from opioids to small molecules: what is new?","volume":"10","author":"Arena","year":"2018","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0310","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","article-title":"The pharmacology of sigma-1 receptors","volume":"124","author":"Maurice","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2024.129654_b0315","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1021\/acs.jmedchem.7b01584","article-title":"(+)-Methyl (1R,2S)-2-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]methyl-1-phenylcyclopropanecarboxylate [(+)-mr200] derivatives as potent and selective sigma receptor ligands: stereochemistry and pharmacological properties","volume":"61","author":"Amata","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0320","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1351\/pac200173091499","article-title":"Opioid and sigma receptor studies. New developments in the design of selective sigma ligands","volume":"73","author":"Ronsisvalle","year":"2001","journal-title":"Pure Appl Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0325","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1021\/acs.jmedchem.6b00472","article-title":"The \u201cCyclopropyl Fragment\u201d is a versatile player that frequently appears in preclinical\/clinical drug molecules","volume":"59","author":"Talele","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129654_b0330","unstructured":"Schr\u00f6dinger Release 2023-2: Jaguar; Schr\u00f6dinger, LLC: New York, 2023; https:\/\/www.schrodinger.com\/products\/jaguar."},{"key":"10.1016\/j.bmcl.2024.129654_b0335","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jmgm.2010.05.008","article-title":"Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods","volume":"29","author":"Duan","year":"2010","journal-title":"J Mol Graph Model"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24000568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24000568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:49:13Z","timestamp":1760773753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24000568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":67,"alternative-id":["S0960894X24000568"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129654","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2-Phenylcyclopropylmethylamine (PCPMA) as a privileged scaffold for central nervous system drug design","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129654"}}